2024
A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis.
Hagen P, Sidana S, Parker T, Walker B, Hoering A, Sanchorawala V, Zonder J, Kourelis T, D'Souza A, Landau H, Rosenthal A, Ailawadhi S, Orlowski R. A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis. Journal Of Clinical Oncology 2024, 42: tps7575-tps7575. DOI: 10.1200/jco.2024.42.16_suppl.tps7575.Peer-Reviewed Original ResearchAutologous stem cell transplantationProgression free survivalStem cell transplantationOverall survivalCell transplantationASCT armNext generation flow cytometryLight chain (AL) amyloidosisDaratumumab to bortezomibDiagnosed AL amyloidosisTwo-sided significance levelPlasma cell malignancyShort follow-upDaratumumab maintenanceMRD negativityFree survivalInduction therapyIntergroup trialMultiple myelomaAL amyloidosisHematologic responseRenal responseRandomized studyCell malignancyFollow-upA Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114)
Hagen P, Hoering A, Sidana S, Parker T, Walker B, Sanchorawala V, Zonder J, Kourelis T, D’Souza A, Landau H, Rosenthal A, Ailawadhi S, Z. R. A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (DARA-VCD) Induction Followed by Autologous Stem Cell Transplant or DARA-VCD Consolidation and Daratumumab Maintenance in patients with Newly Diagnosed AL Amyloidosis PA145 (#114). 2024 DOI: 10.26226/m.65f9bf89e6f73964e1d4eb32.Peer-Reviewed Original Research
2017
2168
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Gan G, Zelterman D, Brandt D, Kortmansky J, Witt D, Dhodapkar M. 2168. Journal Of Clinical And Translational Science 2017, 1: 31-32. PMCID: PMC6799516, DOI: 10.1017/cts.2017.118.Peer-Reviewed Original ResearchPlasma cell disordersInfluenza vaccination strategiesInfluenza vaccinationInfluenza infection ratesVaccination strategiesCell disordersInfluenza infectionClinical correlatesInfection rateInfluenza vaccineRandomized studySingle vaccineDisorder patientsFlu seasonGrade 2 adverse eventsHigh-dose influenza vaccinationHigh-dose influenza vaccineLaboratory-confirmed influenza infectionHigh-dose vaccineSerologic response rateCell-mediated immunityFlu-like illnessNovel vaccination strategiesT cell subpopulationsT cell responsiveness
2016
Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial
Branagan A, Duffy E, Parker T, Seropian S, Foster C, Zhang L, Verma R, Zelterman D, Gan G, Brandt D, Kortmansky J, Witt D, Ferencz T, Dhodapkar M. Lower Rates of Influenza Infection Following Two Dose Series of High Dose Vaccination in Plasma Cell Disorders: Results of a Randomized, Double-Blind, Placebo-Assisted Clinical Trial. Blood 2016, 128: 2139. DOI: 10.1182/blood.v128.22.2139.2139.Peer-Reviewed Original ResearchHigh-dose influenza vaccinePlasma cell disordersInfluenza vaccinationCell-mediated immunityInfluenza vaccineInfluenza infectionCell disordersClinical correlatesVaccination strategiesPCD patientsRandomized studySingle vaccineClinical trialsDose seriesFlu seasonInfection rateHigh-dose influenza vaccinationLaboratory-confirmed influenza infectionTwo-dose vaccination strategyHigh-dose vaccinationHigh-dose vaccineInfluenza vaccination strategiesPresent randomized studySerologic response rateSeasonal influenza vaccination